Fig. 3
Astrocytic APOE4 regulates the distribution of Aβ40 and Aβ42 deposition in plaques, parenchymal vessels, and leptomeningeal vessels. a–d, PBS-soluble and guanidine-HCL-soluble (“insoluble”) Aβ40 and Aβ42 protein concentrations assessed by ELISA from cortex. e–h Aβ40 immunoreactivity (IR) (e) with percent area coverage of total Aβ40 (f), total vascular Aβ40 (g), and Aβ40 in plaques (h). i Proportion of vascular Aβ40 in total Aβ40 IR. j, k Aβ40 IR restricted to pial vessels (j) and penetrating vessels (k). (l) Proportion of vascular Aβ40 in penetrating vessels out of total vascular Aβ40. m–p, Aβ42 immunoreactivity (IR) (m) with percent area coverage of total Aβ42 (n), total vascular Aβ42 (o), and Aβ42 in plaques (p). q Proportion of vascular Aβ42 in total Aβ42 IR. r, s, Aβ42 IR restricted to pial vessels (r) and penetrating vessels (s). t Proportion of vascular Aβ42 in penetrating vessels out of total vascular Aβ42. Blue arrow = vascular Aβ. Purple arrows = plaques. Scalebar: 500 µm. Data expressed as mean ± SD, student’s t-test (two-sided) performed for all statistical analyses except (d), where Welch’s t-test was performed. ∆ = males, ○ = females. *P < 0.05, *P < 0.01, ***P < 0.001, ****P < 0.0001. No other statistical comparisons are significant unless indicated